Aurelius Omlin
About
Aurelius Omlin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Aurelius Omlin has authored 115 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Pulmonary and Respiratory Medicine, 58 papers in Oncology and 35 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Aurelius Omlin's work include Prostate Cancer Treatment and Research (76 papers), Radiopharmaceutical Chemistry and Applications (33 papers) and Prostate Cancer Diagnosis and Treatment (21 papers). Aurelius Omlin is often cited by papers focused on Prostate Cancer Treatment and Research (76 papers), Radiopharmaceutical Chemistry and Applications (33 papers) and Prostate Cancer Diagnosis and Treatment (21 papers). Aurelius Omlin collaborates with scholars based in Switzerland, United Kingdom and United States. Aurelius Omlin's co-authors include Johann S. de Bono, Timothy A. Yap, David Lorente, Carmel Pezaro, Gerhardt Attard, Florian Strasser, Roberta Ferraldeschi, Silke Gillessen, Andrea Zivi and Sabine Schmid and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.
In The Last Decade
Aurelius Omlin
106 papers receiving 3.6k citations
Hit Papers
Author Peers
Peers are selected by citation overlap in the author's most active subfields. citations · hero ref
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Aurelius Omlin | 1.9k | 1.3k | 985 | 816 | 693 | 115 | 3.6k | |
| Umberto Basso | 1.7k 0.9× | 2.1k 1.6× | 736 0.7× | 1.0k 1.2× | 283 0.4× | 236 | 4.7k | |
| Ondřej Topolčan | 1.0k 0.6× | 1.6k 1.2× | 1.1k 1.1× | 1.3k 1.6× | 278 0.4× | 254 | 4.2k | |
| Brett Hughes | 2.1k 1.1× | 2.3k 1.7× | 696 0.7× | 820 1.0× | 252 0.4× | 179 | 4.4k | |
| Jane Huang | 1.1k 0.6× | 999 0.8× | 522 0.5× | 716 0.9× | 352 0.5× | 90 | 4.2k | |
| Masashi Ando | 954 0.5× | 2.0k 1.6× | 774 0.8× | 688 0.8× | 361 0.5× | 206 | 3.6k | |
| Yan‐Ping Mao | 1.8k 0.9× | 2.5k 1.9× | 1.1k 1.1× | 1.0k 1.2× | 1.0k 1.5× | 203 | 6.4k | |
| Jenna Sykes | 2.2k 1.2× | 687 0.5× | 1.0k 1.0× | 1.2k 1.4× | 351 0.5× | 112 | 4.4k | |
| Mark C. Weissler | 1.0k 0.5× | 1.4k 1.0× | 759 0.8× | 1.2k 1.5× | 280 0.4× | 148 | 4.7k | |
| Vincenzo Tombolini | 1.4k 0.7× | 1.5k 1.1× | 515 0.5× | 1.1k 1.3× | 803 1.2× | 224 | 4.4k | |
| Richard Cowan | 2.4k 1.3× | 1.0k 0.8× | 311 0.3× | 743 0.9× | 776 1.1× | 138 | 5.2k |
Countries citing papers authored by Aurelius Omlin
Since
Specialization
Citations
This map shows the geographic impact of Aurelius Omlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurelius Omlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurelius Omlin more than expected).
Fields of papers citing papers by Aurelius Omlin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Aurelius Omlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurelius Omlin. The network helps show where Aurelius Omlin may publish in the future.
Co-authorship network of co-authors of Aurelius Omlin
This figure shows the co-authorship network connecting the top 25 collaborators of Aurelius Omlin. A scholar is included among the top collaborators of Aurelius Omlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurelius Omlin. Aurelius Omlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Aprikian, Armen, et al.. (2025). Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings. Frontiers in Oncology. 15. 1491314–1491314.
2.
Abt, Dominik, Lukas Hechelhammer, Aurelius Omlin, et al.. (2024). Prostatic Artery Embolization in Patients with Advanced Prostate Cancer: A Prospective Single Center Pilot Study. CardioVascular and Interventional Radiology. 47(6). 771–782.
3.
Turco, Fabio, Bertrand Tombal, Silke Gillessen, & Aurelius Omlin. (2024). Is There a Place for De-escalating Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer?. European Urology Focus. 10(4). 518–521.
4.
Omlin, Aurelius, Richard Cathomas, Gunhild von Amsberg, et al.. (2023). Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(10). 1887–1893.
5.
Gillessen, Silke, Giuseppe Procopio, Stefanie Hayoz, et al.. (2023). Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). Journal of Clinical Oncology. 41(20). 3608–3615.
6.
Petrausch, Ulf, Martin Spahn, Martina Schneider, et al.. (2023). Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19). BMJ Open. 13(6). e067634–e067634.
7.
Fischer, Stefanie, Thorsten Oliver Götze, Aurelius Omlin, et al.. (2022). A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. JCO Precision Oncology. 6(6). e2200006–e2200006.
8.
Beyer, J., Dominik Berthold, Richard Cathomas, et al.. (2021). Swiss germ-cell cancer consensus recommendations. Swiss Medical Weekly. 151(3334). w30023–w30023.
9.
Antonarakis, Emmanuel S., Josep M. Piulats, Marine Gross‐Goupil, et al.. (2021). 611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study. Annals of Oncology. 32. S651–S652.
10.
McDermott, Ray, Emmanuel S. Antonarakis, Christopher Hoimes, et al.. (2020). KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). European Urology Open Science. 19. e885–e886.
11.
Omlin, Aurelius, Julie N. Graff, Christopher Hoimes, et al.. (2020). 623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update. Annals of Oncology. 31. S514–S515.
12.
Pérez-López, Raquel, Nina Tunariu, Anwar R. Padhani, et al.. (2019). Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology. 292(2). 273–286.
13.
Middleton, Mark R., Sanjeev Kumar, Jordi Rodón, et al.. (2016). Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors. Annals of Oncology. 27. vi115–vi115.
14.
Lorente, David, Praful Ravi, Niven Mehra, et al.. (2016). Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus. 4(2). 235–244.
15.
Leibowitz‐Amit, Raya, Arnoud J. Templeton, Aurelius Omlin, et al.. (2014). Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Annals of Oncology. 25(3). 657–662.
16.
Schmid, Sabine, Jürgen Fornaro, Christian Rothermundt, et al.. (2014). Abiraterone—What Is Wrong With the Adrenal Glands?. Clinical Genitourinary Cancer. 12(4). e133–e137.
17.
Loriot, Yohann, Karim Fizazi, Robert J. Jones, et al.. (2014). Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Investigational New Drugs. 32(5). 995–1004.
18.
Bianchini, Diletta, Aurelius Omlin, Carmel Pezaro, et al.. (2013). First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British Journal of Cancer. 109(10). 2579–2586.
19.
Laurent, Julien, Cédric Touvrey, Silke Gillessen, et al.. (2013). T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. Journal of Translational Medicine. 11(1). 5–5.
20.
Omlin, Aurelius, Kathrin Mühlemann, Martin F. Fey, & Thomas Pabst. (2005). Pneumococcal vaccination in splenectomised cancer patients. European Journal of Cancer. 41(12). 1731–1734.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Umberto Basso Breakdown of academic impact, for papers by Ondřej Topolčan Breakdown of academic impact, for papers by Brett Hughes Breakdown of academic impact, for papers by Jane Huang Breakdown of academic impact, for papers by Masashi Ando Breakdown of academic impact, for papers by Yan‐Ping Mao Breakdown of academic impact, for papers by Jenna Sykes Breakdown of academic impact, for papers by Mark C. Weissler Breakdown of academic impact, for papers by Vincenzo Tombolini Breakdown of academic impact, for papers by Richard Cowan